Cetuximab Recruiting Phase 2 Trials for Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03646461Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
NCT02624128Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck